⌕
Sionna Therapeutics · SION · Nasdaq
Tenet 70 · Solid
Compare
$3.12−6.31%At closeTenet 70 · Solid
$3.12−0.21 (−6.31%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Sionna Therapeutics (SION) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● GlobeNewsWireNov 10, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Sionna Therapeutics Reports Third Quarter 2026 Financial Results

Advancing SION-451 + SION-2222 dual combination to AscenSION CF Phase 2 proof-of-concept trial, expected to initiate in the first quarter of 2027…

● GlobeNewsWireNov 2, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Sionna Therapeutics to Participate in Upcoming November 2026 Investor Conferences

WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to develop novel medicines for cystic fibrosis (CF), today announced tha…

● Zacks Investment ResearchOct 12, 2026 · 10:35 ET
Sionna Therapeutics, Inc. (SION) Loses 37.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Sionna Therapeutics, Inc. (SION) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ear…

● GlobeNewsWireOct 8, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference

Previously disclosed post hoc PreciSION CF analyses of SION-719 support advancement of SION-451 + SION-2222 into the AscenSION CF Phase 2a proof-of-concept trial New preclinical data evaluating NBD1 stabilizers in combin…

● Defense WorldOct 8, 2026 · 04:29 ET
Sionna Therapeutics, Inc. (NASDAQ:SION) Stock Has Average Target Price of $42.33 According to Brokerages

Sionna Therapeutics, Inc. (NASDAQ: SION - Get Free Report) has been given an average recommendation of "Hold" by the thirteen ratings firms that are currently covering the company, Marketbeat reports. One investment anal…

● GlobeNewsWireOct 6, 2026 · 18:37 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION). Such investors are advised to contact Dani…

● PRNewsWireOct 1, 2026 · 10:00 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. ("Sionna" or the "Company") (NASDAQ: SION). Such investors are advised to contact Danielle …

● PRNewsWireSep 24, 2026 · 17:34 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. ("Sionna" or the "Company") (NASDAQ: SION).…

● PRNewsWireSep 17, 2026 · 10:00 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. ("Sionna" or the "Company") (NASDAQ: SION).…

● Zacks Investment ResearchSep 16, 2026 · 12:31 ET
SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down

Sionna set to reduce its workforce by 46% after SION-719 fails a key CF study, shifting focus to SION-451 + SION-2222.…

● Defense WorldSep 16, 2026 · 01:29 ET
Brokerages Set Sionna Therapeutics, Inc. (NASDAQ:SION) Price Target at $42.22

Sionna Therapeutics, Inc. (NASDAQ: SION - Get Free Report) has earned a consensus rating of "Hold" from the thirteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. One equities research …

● Seeking AlphaSep 15, 2026 · 06:31 ET
Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement of Dual Combination Program Transcript

Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement of Dual Combination Program Transcript…

● GlobeNewsWireSep 14, 2026 · 16:01 ET
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial

Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activity…

● PRNewsWireSep 10, 2026 · 10:00 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. ("Sionna" or the "Company") (NASDAQ: SION).…

● GuruFocusSep 3, 2026 · 11:00 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION PR Newswire…

● GlobeNewsWireSep 2, 2026 · 14:54 ET
SIONNA THERAPEUTICS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Sionna Therapeutics Inc on Behalf of Sionna Therapeutics Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Sionna Therapeutics (SION) To Contact Him Directly To Discuss Their Options…

● GlobeNewsWireAug 31, 2026 · 09:01 ET
SION INVESTIGATION: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

SAN DIEGO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Sionna Therapeutics, Inc. (NASDAQ: SION). If you have any info…

● PRNewsWireAug 27, 2026 · 16:45 ET
INVESTIGATION ALERT: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - SION

SAN DIEGO, Aug. 27, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP  is investigating potential violations of United States federal securities laws involving Sionna Therapeutics, Inc. (NASDAQ: SION). If you any hav…

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just SION · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.